| Target
Information |
| Name | Proliferating cell nuclear antigen |
| Type of target | Research target |
| Synonyms | Cyclin |
| PCNA |
| Disease | Cardiovascular disease, unspecified [1] |
| Pathway | Base excision repair |
| Cell cycle |
| DNA replication |
| Mismatch repair |
| Nucleotide excision repair |
| UniProt ID | P12004 |
| PDB Structure | 1AXC; 1U76; 1U7B; 1UL1; 1VYJ; 1VYM; 1W60; 2ZVK. |
| Function | This protein is an auxiliary protein of dna polymerase delta and is involved in the control of eukaryotic dna replication by increasing the polymerase's processibility during elongation of the leading strand. |
| Sequence | MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTY
RCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMD
LDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNI
KLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYK
IADMGHLKYYLAPKIEDEEGS
|
| Target Validation | Click to Find Target Validation Information. |
| Inhibitor | 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide |  | [2] |
| 3- ( |  | [3] |
| 4- (7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol |  | [4] |
| 4- (phenyldiazenyl)-1H-pyrazole-3,5-diamine |  | [3] |
| 4-[ (3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol |  | [3] |
| 6- (3-Amino-benzyloxy)-9H-purin-2-ylamine |  | [5] |
| 6- (3-Methyl-benzyloxy)-9H-purin-2-ylamine |  | [5] |
| 6- (Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine |  | [5] |
| 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine |  | [6] |
| GW-8510 |  | [7] |
| MERIOLIN 1 |  | [8] |
| MERIOLIN 2 |  | [8] |
| MERIOLIN 3 |  | [8] |
| MERIOLIN 4 |  | [8] |
| MERIOLIN 5 |  | [8] |
| MERIOLIN 6 |  | [8] |
| MERIOLIN 7 |  | [8] |
| MERIOLIN 8 |  | [8] |
| NU-2058 |  | [9] |
| NU-6027 |  | [6] |
| PD-0183812 |  | [10] |
| PURVALANOLA |  | [11] |
| RESCOVITINE |  | [12] |
| SB-216763 |  | [13] |
| Cross References |
3D Structure
Related Literature
On-Line
Medical Dictionary |
| Ref 1 | Apoptosis and proliferation of cardiomyocytes in heart failure of different etiologies. Cardiovasc Pathol. 2000 May-Jun;9(3):149-52. To Reference |
| Ref 2 | Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010) To Reference |
| Ref 3 | J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. To Reference |
| Ref 4 | J Med Chem. 2003 Jan 16;46(2):222-36.Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. To Reference |
| Ref 5 | J Med Chem. 2002 Aug 1;45(16):3381-93.Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. To Reference |
| Ref 6 | Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. To Reference |
| Ref 7 | Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. To Reference |
| Ref 8 | J Med Chem. 2008 Feb 28;51(4):737-51. Epub 2008 Jan 31.Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. To Reference |
| Ref 9 | J Med Chem. 2004 Jul 15;47(15):3710-22.N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. To Reference |
| Ref 10 | J Med Chem. 2000 Nov 30;43(24):4606-16.Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. To Reference |
| Ref 11 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. To Reference |
| Ref 12 | Eur J Med Chem. 2010 Mar;45(3):1158-66. Epub 2009 Dec 21.Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. To Reference |
| Ref 13 | J Med Chem. 2010 Feb 11;53(3):994-1003.Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. To Reference |